ProShare Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $428K | Buy |
84,553
+12,300
| +17% | +$62.2K | ﹤0.01% | 1206 |
|
|
2025
Q1 | $382K | Sell |
72,253
-15,905
| -18% | -$84.1K | ﹤0.01% | 1246 |
|
|
2024
Q4 | $596K | Buy |
88,158
+26,847
| +44% | +$181K | ﹤0.01% | 1173 |
|
|
2024
Q3 | $404K | Buy |
61,311
+28,434
| +86% | +$187K | ﹤0.01% | 1269 |
|
|
2024
Q2 | $247K | Sell |
32,877
-8,072
| -20% | -$60.5K | ﹤0.01% | 1415 |
|
|
2024
Q1 | $408K | Buy |
40,949
+5,051
| +14% | +$50.4K | ﹤0.01% | 1210 |
|
|
2023
Q4 | $354K | Buy |
35,898
+4,829
| +16% | +$47.6K | ﹤0.01% | 1265 |
|
|
2023
Q3 | $238K | Buy |
31,069
+1,372
| +5% | +$10.5K | ﹤0.01% | 1358 |
|
|
2023
Q2 | $222K | Buy |
29,697
+895
| +3% | +$6.69K | ﹤0.01% | 1469 |
|
|
2023
Q1 | $192K | Sell |
28,802
-3,809
| -12% | -$25.4K | ﹤0.01% | 1468 |
|
|
2022
Q4 | $251K | Buy |
32,611
+3,707
| +13% | +$28.6K | ﹤0.01% | 1341 |
|
|
2022
Q3 | $308K | Buy |
28,904
+954
| +3% | +$10.2K | ﹤0.01% | 1136 |
|
|
2022
Q2 | $227K | Sell |
27,950
-10,157
| -27% | -$82.5K | ﹤0.01% | 1395 |
|
|
2022
Q1 | $272K | Sell |
38,107
-9,542
| -20% | -$68.1K | ﹤0.01% | 1692 |
|
|
2021
Q4 | $816K | Buy |
+47,649
| New | +$816K | ﹤0.01% | 1155 |
|
|
2021
Q3 | – | Sell |
-5,482
| Closed | -$200K | – | 2219 |
|
|
2021
Q2 | $200K | Buy |
+5,482
| New | +$200K | ﹤0.01% | 2144 |
|